Male hormonal contraception

Bibliography

• UNITED NATIONS FAMILY PLANNING ASSOCIATION. Report of the International Conference on Population Development. New York: United Nations (1994).
   Google Scholar
• MCLACHLAN RI, O'DONNEL L, MEACHEM SJ et al.: Identification of specific sites of hormonal regulation of spermatogenesis in rats, monkeys, and man. Recent Frog. Horm. Res. (2002) 57:149–179.
   PubMedGoogle Scholar
• WORLD HEALTH ORGANIZATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Contraceptive efficacy of testosterone-induced azoospermia by testosterone enanthate in normal men. Lancet (1990) 336:995–999.
   Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Contraceptive efficacy of testosterone-induced azoospermia or oligozoospermia by testosterone enanthate in normal men. Feral Sterd. (1996) 65:821–829.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, FARLEY TM, PEREGOUDOV A, WAITES GMH: Factors in nonuniform induction of azoospermia by testosterone enanthate in men. Fertil. Steil]. (1995) 63:125–133.
   PubMed Web of Science ®Google Scholar
• VON ECKARDSTEIN A, BUCHTER D, NIESCHLAG E: Successful treatment of male hypogonadism with testosterone undecanoate (TU) in extended intervals of 12 weeks. VII International Congress of Andrology, Montreal, Canada (2001).
   Google Scholar
• ZHANG GY, GU YQ, WANG XH, CUI Y, BREMNER WJ: A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J. Andra (1998) 19:761–768.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, ABSHAGEN K,OETTEL M, HUBLER D,NIESCHLAG E: Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: Phase I studies. Ear: .1. Endocrinol (1999) 140:414-419. 9.ZHANG GY, GU YQ, WANG XH, CUI YG, BREMNER WJ: A clinical trial of injectable testosterone undecanoate as a potential contraceptive in normal Chinese men. I Clin. Endocrinol Metab. (1999) 84:3642–3647.
   Google Scholar
• KAMISCHKE A, PLOGER D, VENHERM S et al.: Intramuscular testosterone undecanoate with or withoutoral levonorgestrel: a randomized placebo-controlled study for male contraception. Clin. Endocrinol (2000) 53:43–52.
   PubMed Web of Science ®Google Scholar
• GU YQ, WANG XH, XU D et al.: A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. I Clin. EndocrinoL Metab. (2003) 88:562–568.
   Google Scholar
• KHOSLA S, MELTON J, RIGGS BL: Estrogen and the male skeleton. J. Clin. EndocrinoL Metab. (2003) 87:1443–1450.
   Web of Science ®Google Scholar
• CUMMINGS DE, KUMAR N, BARDIN CW, SUNDARAM K, BREMNER WJ: Prostate-sparing effects in primates of the potent androgen 7 alpha-methy1-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. Clin. Endocrinol Metab. (1998) 83:4212–4219.
   Google Scholar
• ANDERSON AM, WALLACE AM, SATTAR N, KUMAR N, SUNDARAM K: Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. Clin. Endocrinol Metab. (2003) 88:2784–2793.
   Google Scholar
• ANDERSON RA, MARTIN CW, KUNG AW et al.: 7 alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J. Clin. EndocrinoL Metab. (1999) 84:3556–3562.
   PubMed Web of Science ®Google Scholar
• SUVISAARI J, SUNDRAM K, NOE G et al.: Pharmacokinetics and pharmacodynamics of 7 alpha-methyl-19-nortestosterone after intramuscular administration in healthy men. Hum. Reprod. (1997) 12:967–973.
   PubMed Web of Science ®Google Scholar
• NOE G, SUVISAARI J, MARTIN C et al.:Gonadotropin and testosterone suppression by 7 alpha-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men. Hum. Reprod. (1999) 14:2200–2206.
   PubMed Web of Science ®Google Scholar
• VON ECKARDSTEIN S, NOE G, BRACHE V et al.: A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. Clin. Endocrinol Metab. (2003) 88:5232–5239.
   Google Scholar
• HAMMAN LG, HIGUCHI RI, ZHI L et al.: Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective, androgen receptor antagonists derived from 1,2-dihydropyridono quinolines. I Med. Chem. (1998) 41:623–639.
   Web of Science ®Google Scholar
• HAMMAN LG, MANI NS, DAVIS RL et al.: Discovery of a potent orally active, nonsteroidal androgen receptor agonist: 4-ethy1-1,2,3,4-tetrahydro-6-(trifluormethyl)-8-pyridino [5,60 -quinoline (LG121071). Med. Chem. (1999) 84:3459–3462.
   Google Scholar
• HELLER CG, LAIDLAW WM, HARVEY HT, NELSON WO: Effects of progestational compounds on the reproductive processes of the human male. Ann. NY Acad. ScL (1958) 71:649–665.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA MC, FARLEY TMM, MBIZVO MT: A review of androgen-progestin combinations for male contraception. J. AndroL (2003) 24:466–483.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ: Hormonal male contraception: lessons from the East when the Western market fails. I Clin. Endocrinol Metab. (2003) 88:559–561.
   PubMed Web of Science ®Google Scholar
• BEBB RA, ANAWALT BD, CHRISTENSEN RB et al.: Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. Clin. Endocrinol Metab. (1996) 81:3018–3023.
   Google Scholar
• MCLACHLAN RI, ROBERTSON DM, PRUYSERS E et al.: Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J. Clin. Endocrinol Metab. (2004) 89:142–149.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Comparison of two androgens plus depot-medroxyprogestrone acetate for suppression to azoospermia in Indonesian men. Feral Sterd. (1993) 60:1062–1068.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, CONWAY AJ, HOWE CJ, TURNER L, MACKEY MA: Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J. Clin. Endocrinol Metab. (1996) 81:4113–4121.
   PubMed Web of Science ®Google Scholar
• TURNER L, CONWAY AJ, JIMENEZ M et al.: Contraceptive efficacy of a depot progestin and androgen combination in men. I Clin. Endocrinol Metab. (2003) 88:4659–4667.
   Google Scholar
• KAMISCHKE A, VENHERM S, PLOD GER D, VON ECKARDSTEIN S, NIESCHLAG E: Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trialfor male contraception. J. Clin. Endocrine] Metab. (2001) 86:303–309.
   PubMed Web of Science ®Google Scholar
• KAMISCHKE A, HEUERMANN TESTOSTERONE, KRUGER K et al.: An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. Clin. Endocrine] Metab. (2002) 87:530–539.
   PubMed Web of Science ®Google Scholar
• ANDERSON RA, KINNIBURGH D, BAIRD DT: Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J. Clin. Endocrine]. Metab. (2002) 87:3640–3649.
   PubMed Web of Science ®Google Scholar
• ANAWALT BD, BEBB RA, BREMNER WJ, MATSUMOTO AM: A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J. Andre] (1999) 20:407–413.
   PubMed Web of Science ®Google Scholar
• BUCHTER D, VON ECKARDSTEIN S, VON ECKARDSTEIN A et al.: Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. Clin. Endocrine]. Metab. (1999) 84:1244–1249.
   PubMed Web of Science ®Google Scholar
• GONZALO ITG, SWERDLOFF RS, NELSON AL et al.: Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J. Clin. Endocrine]. Metab. (2002) 87:3562–3572.
   PubMed Web of Science ®Google Scholar
• WANG C, CUNNINGHAM G, DOBS A et al.: Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. I Clin. Endocrine]. Metab. (2004) 89:2085–2098.
   PubMed Web of Science ®Google Scholar
• WU FCW, BALASUBRAMANIAN R, MULDERS TMT, COELINGH-BENNICK HJT: Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism.' Chu. Endocrine]. Metab. (1999) 84:112–122.
   PubMed Web of Science ®Google Scholar
• ANAWALT BD, HERBST KL, MATSUMOTO AM, MULDERS TM, COELINGH-BENNICK HJ, BREMNER WJ: Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Feral. Sterd. (2000) 74:707–714.
   PubMed Web of Science ®Google Scholar
• MARTIN CW, RILEY SC, EVERINGTON D et al.: Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men. Hum. Reprod. (2000) 15:1515–1524.
   PubMed Web of Science ®Google Scholar
• KINNIBURGH D, ZHU H, CHENG L, KICMAN AT, BAIRD DT, ANDERSON RA: Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum. Reprod. (2002) 17:1490–1501.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA MC, BREMNER WJ, PAULSEN C et al.: A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J. Clin. Endocrine]. Metab. (1996) 81:3018–3023.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA MC, BREMNER WJ, CONSTANTINO A, DI CINTIO G, FLAMIGNI C: Low dose cyproterone actetate and testosterone enanthate for contraception in men. Hum. Reprod. (1998) 13:1225–1229.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA MC, CONSTANTINO A, BREMNER WJ, MORSELLI-LABATE AM: Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen. J. Andrei (2002) 23:684–689.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA MC, CONSTANTINO A, CERPOLINI S et al.: Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. I Clin. Endocrine]. Metab. (2003) 88:5818–5826.
   PubMed Web of Science ®Google Scholar
• SWERDLOFF RS, BAGATELL CJ, WANG C et al.: Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. I Clin. Endocrine]. Metab. (1998) 83:3527–3533.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA MC, BREMNER WJ, CONSTANTINO A, PAVANI A, CAPELLI M, FLAMIGNI C: An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil. Steil]. (1997) 68:844–850.
   PubMed Web of Science ®Google Scholar
• CUMMINGS DE, BREMNER WJ: Prospects for new hormonal male contraceptives. Endocrine]. Metab. Clin. North Am. (1994) 23:893–922.
   PubMed Web of Science ®Google Scholar
• PAVLOU SN, BREWER K, FARLEY MG et al.: Combined administration of a gonadotropin-releasing antagonist and testosterone in men induces reversible azoospermia without loss of libodo. Clin. Endocrine]. Metab. (1991) 73:1360–1369.
   PubMed Web of Science ®Google Scholar
• TOM L, BHASIN S, SALAMEH W et al.:Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. Clin. Endocrine]. Metab. (1992) 75:476–483.
   PubMed Web of Science ®Google Scholar
• BAGATELL CJ, MATSUMOTO AM, CHRISTENSEN RB, RIVIER JE, BREMNER WJ: Comparison of a gonadotropin-releasing antagonist plus testosterone (testosterone) versus testosterone alone as potential male contraceptive regimens. " Clin. Endocrine]. Metab. (1993) 77:427–432.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, KLIESCH S, LEMCKE B, VON ECKARDSTEIN S, NIESCHLAG E: Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nor testosterone cannot be maintained by this non-aromatizable androgen alone. Hum. Reprod. (2001) 16:2570–2577.
   PubMed Web of Science ®Google Scholar
• BAGATELL CJ, DAHL KD, BREMNER WJ: The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol. I Andrei (1994) 15:15–21.
   PubMed Web of Science ®Google Scholar
• HERBST KL, ANAWALT BD, AMORY JK, BREMNER WJ: Acyline: the first study in humans of a potent, gonodotropin-releasing hormone antagonist. I Clin. Endocrine]. Metab. (2002) 87:3215–3220.
   PubMed Web of Science ®Google Scholar
• CHO N, HARADA M, IMEDA TESTOSTERONE et al.: Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. I Med. Chem. (1998) 41:4190–4195.
   Web of Science ®Google Scholar
• BESECKE L, DIAZ G, SEGRETI TESTOSTERONE et al.: Pharmacological and endocrine characterization of A-19840, an orally active GnRH antagonist in intact and castrate male rat models. Drug Dev. Res. (2001) 52:485–491.
   Web of Science ®Google Scholar
• MARTIN CW, ANDERSON RA, CHENG L et al.: Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum. Reprod. (2000) 15:637–645.
   PubMed Web of Science ®Google Scholar
• GLASIER AF, ANAKWE R, EVERINGTON D et al.: Would women trust their partners to use a male pill? Hum. Reprod. (2000) 15:646–649.
   PubMed Web of Science ®Google Scholar
• HERBST KL, ANAWALT BD, AMORY JK, MATSUMOTO AM, BREMNER WJ: The male contraceptive regimen of testosterone and levonorgestrel significantly increases lean mass in healthy young men in 4 weeks, but attenuates a decrease in fat mass induced by testosterone alone. Clio. Endocrinol Metab. (2003) 88:1167–1173.
   PubMed Web of Science ®Google Scholar
• EXECUTIVE SUMMARY OF THE THIRD REPORT OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP): Expert panel on detection, evaluation, and treatment of high blood cholesterol in adult (Adult Treatment Panel III). PIMA (2001) 285:2486–2497.
   Google Scholar
• LIU PY, DEATH AK,HANDELSMAN DJ: Androgens and cardiovascular disease. Endocr: Rev (2003) 24:313–340.
   PubMed Web of Science ®Google Scholar
• SANTNER SJ, ALBERTSON B, ZHANG GY et al.: Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. I. Clio. Endocrinol Metab. (1998) 83:2104–2109.
   PubMed Web of Science ®Google Scholar
• WANG C, BERMAN NG, VELDHUIS JD et al.: Graded testosterone infusions distinguish gonadotropin negative-feedback responsiveness in Asian and white men — a clinical research center study. Clio. Endocrinol Metab. (1998) 83:870–876.
   PubMed Web of Science ®Google Scholar
• WEINBAUER GE SCHLATT S, WALTER V, NIESCHLAG E: Testosterone induced inhibition of spermatogenesis is more closely related to suppression of FSH than to testicular androgen levels in the cynomolgus monkey (Maraca fasicularis). Endocrinol (2001) 168:25–38.
   PubMed Web of Science ®Google Scholar
• ANDERSON RA, WALLACE AM, WU FC: Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive. III. Higher 5-alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. Clin. Endocrinol Metab. (1996) 81:902–908.
   Google Scholar
• MCLACHLAN RI, MCDONALD J, RUSHFORD D et al.: Efficacy and acceptability of testosterone implants, alone or in combination with a 5-alpha-reductase inhibitor, for male hormonal contraception. Steril. (2000) 62:73–78.
   Google Scholar
• KINNIBURGH D, ANDERSON RA, BAIRD DT: Suppression of spermatogenesis with desogestrel pellets is not enhanced by the addition of finasteride. J. Andra (2001) 22:88–95.
   PubMed Web of Science ®Google Scholar